High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study

A. Veronesi; V. Zagonel; U. Tirelli; E. Galligioni; S. Tumolo; L. Barzan; M. Lorenzini; R. Comoretto; E. Grigoletto

High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study

A. Veronesi, V. Zagonel, U. Tirelli, E. Galligioni, S. Tumolo, L. Barzan, M. Lorenzini, R. Comoretto, E. Grigoletto

Research output: Contribution to journal › Article

Abstract

From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m²) or low-dose (60 mg/m²) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.

Original language	English
Pages (from-to)	1105-1108
Number of pages	4
Journal	Journal of Clinical Oncology
Volume	3
Issue number	8
Publication status	Published - 1985

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study'. Together they form a unique fingerprint.

Cite this

@article{7a1ef1adf56a4a36bf49c98ae910ea6e,

title = "High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study",

abstract = "From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.",

author = "A. Veronesi and V. Zagonel and U. Tirelli and E. Galligioni and S. Tumolo and L. Barzan and M. Lorenzini and R. Comoretto and E. Grigoletto",

year = "1985",

language = "English",

volume = "3",

pages = "1105--1108",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "8",

}

TY - JOUR

T1 - High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma

T2 - A randomized study

AU - Veronesi, A.

AU - Zagonel, V.

AU - Tirelli, U.

AU - Galligioni, E.

AU - Tumolo, S.

AU - Barzan, L.

AU - Lorenzini, M.

AU - Comoretto, R.

AU - Grigoletto, E.

PY - 1985

Y1 - 1985

N2 - From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.

AB - From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.

UR - http://www.scopus.com/inward/record.url?scp=0021843171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021843171&partnerID=8YFLogxK

M3 - Article

C2 - 4040550

AN - SCOPUS:0021843171

VL - 3

SP - 1105

EP - 1108

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -